Welcome to our dedicated page for Visionary Holdings news (Ticker: GV), a resource for investors and traders seeking the latest updates and insights on Visionary Holdings stock.
Visionary Holdings Inc. (Nasdaq: GV) generates news at the intersection of education, health management, anti-aging medical aesthetics, and regenerative medicine. Company announcements describe an ongoing strategic transformation from a traditional education- and real estate-focused business toward a diversified platform centered on high-end medical aesthetics and big health technology, with AI-enabled education remaining as a supplementary division.
News coverage for GV includes updates on its fiscal year 2025 annual report, where the company outlined progress in its business restructuring and reported initial revenue contributions from emerging health-related businesses. Releases also detail Visionary Holdings' focus on health management initiatives, including gastrointestinal health management and early-stage commercialization efforts in Asia.
Another key stream of news relates to regenerative medicine and stem cell technology. Visionary Holdings has reported a Global Product and Technology Licensing Agreement with Jiangsu Yike Regenerative Medicine Co., Ltd., the creation of Visionary Yike Stemcell Technologies Inc. in Canada, and the launch of a stem cell-based anti-aging product line through its Visionary Health Technology Group Limited subsidiary. These items highlight the company’s emphasis on stem cell therapy, cellular rejuvenation, and premium anti-aging offerings in Asian markets.
Governance and compliance developments are also prominent in GV’s news. The company has announced board renewal, the formation of specialized committees, leadership changes, and auditor appointments, as well as a Nasdaq notification regarding a delayed Form 20-F filing and its plan to regain compliance. Additional releases describe Visionary Holdings’ controlling stake in a joint venture focused on Traditional Chinese Medicine health preservation.
Investors and observers reviewing GV news can expect updates on strategic partnerships, joint ventures, product launches in anti-aging and regenerative medicine, governance changes, and disclosures related to its education and health businesses.
Visionary (Nasdaq: GV) completed an equity adjustment on Oct 17, 2025 and obtained a 51% controlling stake in Sikang (Guangzhou) Health Industry Investment, turning a prior strategic cooperation into capital-driven control.
The move aims to combine Visionary's global capital channels with Guangzhou Sikang's TCM operating ecosystem to scale standardized TCM health preservation services domestically and internationally, including September 22, 2025 market entry in Malaysia and an October 7, 2025 Panyu cooperation conference with over 200 partners.
Forward-looking risks cited include changes in global demand, cross-border compliance adjustments, intensified competition, and potential operational inefficiencies.
Visionary Holdings (Nasdaq: GV) announced on October 13, 2025 that its subsidiary secured a global product and technology licensing agreement with Jiangsu Yike Regenerative Medicine, granting GV worldwide rights to Yike's stem cell technology platform.
The collaboration targets stem cell therapies for Type 1 and Type 2 diabetes, anti‑aging biological repair, and cellular rejuvenation, with clinical trials said to show potential for long‑term remission and possible complete cure. The deal uses a revenue‑sharing model: Yike focuses on licensing and clinical R&D while GV provides global commercialization, clinical channels, and brand operations. The announcement cites a >$150 billion global diabetes treatment market and 540 million affected adults as strategic opportunity.
Visionary Holdings (GV) mailed its Notice of Meeting and Management Information Circular to shareholders of record as of September 12, 2025 for the 2025 Annual Meeting to be held on October 29, 2025 at 10:00 a.m. ET at 19 W 26th St, 5th Fl, New York, NY, with remote attendance via ZOOM.
Agenda items include: electing nine directors, ratifying Assentsure PAC as auditors for the year ended March 31, 2025, and other business. The Company will file its Annual Report on Form 20-F for the year ended March 31, 2025 with the SEC and will provide copies on request.
Voting options: return the Proxy Card, vote in person, or follow the stated online/email procedures (email: lowelltoronto@hotmail.com). Record shareholder list available for inspection 10 days before the meeting. A single holder, 3888 Investment Group, holds 1,516,668 Class B shares (~26.49% of shares) and Class B shares carry 100 votes each (~97.30% of voting power).
Visionary Holdings (Nasdaq: GV) has announced a strategic partnership between its subsidiary Visionary Holdings (Asia) Limited and Qianxin Bocheng, a Jiangsu-based industrial park operator and accelerator. The three-year agreement focuses on advancing the aesthetic treatment industry through four key initiatives:
The collaboration encompasses industrial park development, project incubation, enterprise cultivation with M&A opportunities, and brand promotion activities. Qianxin Bocheng will provide policy support, funding, and facilities, while Visionary Holdings will contribute operational expertise, capital resources, and international experience.
A joint working group will be established to oversee implementation and strategic decision-making. The partnership aims to create an integrated model combining industry, capital, and policy support to foster innovation in the aesthetic treatment sector.
Visionary Holdings (NASDAQ:GV) has announced a strategic partnership with Jiangsu Yike Regenerative Medicine to enter the cellular rejuvenation and aesthetic treatment market. Under the agreement, Yike will lead and fund R&D efforts, while GV may acquire or license the resulting intellectual property through cash or share payments.
The collaboration focuses on three core areas: Cell Activation and Telomerase Homeostasis, utilizing Yike's proprietary Cell-Activating Complex; Smart Delivery and Personalized Solutions, leveraging Nano-Delivery™ technology; and Stem Cell and Immune Cell Applications for aesthetic and healthcare innovations. The partnership will be supported by renowned aging expert Dr. Zhenyu Ju, Yike's Chief Scientist and Dean of the Institute of Aging and Regenerative Medicine at Jinan University.
Visionary Holdings' subsidiary Changle Shuang has formed a strategic partnership with the Guangzhou Jianjia Charity Foundation to launch a nationwide free Helicobacter pylori (Hp) screening campaign in China. The initiative, titled "Healthy Stomach Future, Early Screening for Peace of Mind," aims to provide free Hp testing services to 10 million users.
The campaign addresses a significant health concern in China, where Hp infection rates range from 40%-60%, with 70% of infected individuals showing no obvious symptoms. Changle Shuang, specializing in gastrointestinal microecology nutrition and health, will contribute its patented probiotic technology and professional services to support the screening program.
Visionary Holdings (GV) has announced critical changes to its digital infrastructure following a malicious IT attack that compromised their original website and email systems. The company reported that their previous website (www.visiongroupca.com) and corporate email (@farvision.ca) were hacked, leading to complete system breakdown and potential data security risks.
In response, the company has immediately deactivated these compromised channels and launched new official communication platforms: website www.visionary.holdings and corporate email suffix @visionary.holdings. All stakeholders are required to update their contact information and re-verify cooperation details through the new website.
Visionary Holdings (Nasdaq: GV) announced a significant strategic restructuring through a special shareholders meeting and board meetings. The company elected five new directors with expertise across biotechnology, medical technology R&D, new energy vehicles, education, and finance.
The newly appointed leadership includes Fan Zhou as Chairman and CEO, Jun Huang as COO, and Xiyong Hou as Co-CEO. Weixing Wang, Jinchao Miao, and Yongheng Hu will chair the nomination, audit, and compensation committees respectively.
The restructuring aims to optimize corporate governance, increase investment in high-tech projects, and address previous operational management issues. The company emphasizes compliance with OBCA, Nasdaq, and SEC standards, planning additional compliance training programs for directors, management, and employees.
Visionary Holdings (Nasdaq: GV) has announced strategic expansion plans in the Asia-Pacific region through two key initiatives. On March 3, 2025, the company established Visionary Holdings (Asia) , a wholly-owned subsidiary headquartered in Hong Kong with an additional office in Shenzhen. Mr. Jun Huang has been appointed as CEO to oversee market development and customer service in the region.
Additionally, on March 10, 2025, the company launched a financial platform in Hong Kong, which will serve as the core hub for the group's financial operations in Asia-Pacific. The company is currently pursuing necessary licenses from the Securities and Futures Commission of Hong Kong to support its PEGASUS New Energy Vehicles division by building a global financial supply chain.